CD38 and cancer: Given that NAD+-mediated signaling events include transcription, cell cycle progression and metabolic regulation (Chiarugi et al., 2012), silencing CD38, a key molecule that consumes NAD+, is seemingly the right strategy for fast-dividing cancer cells to increase NAD+ availability (Mottahedeh et al., 2018).